FGF19 can also ameliorate sarcopenia and skeletal muscle atrophy induced by glucocorticoid treatment or obesity, suggesting that FGF19 and its analogs has potential therapeutic application for these symptoms. The gene discussed is FGF19; the disease is obesity disorder.